Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Procedure for approval ...

    Procedure for approval of FDC drugs: CDSCO releases notification; Details

    Meghna A SinghaniaBy Meghna A SinghaniaPublished On 2019-05-24T18:12:04+05:30  |  Updated On 2021-08-17T11:59:52+05:30

    New Delhi: Through a recent notification, the Central Drugs Standard Control Organization (CDSCO) has directed drug manufacturers and all the concerned stakeholders to follow a procedure for clearance of the Fixed-dose Combinations (FDCs) which require a generation of data.


    This comes in response to CDSCO's letter whereby all the State/UT Drugs Controllers were instructed to ask the concerned manufacturers in their State to prove the safety and efficacy of FDCs within 18 months which were permitted by State Licensing Authorities without due approval from the office of DCG(I).


    After examination of such applications in consultation with Prof. Kokate Committee constituted by the Ministry of Health and Family Welfare, concerned manufacturers were earlier asked to conduct Phase IV study in the postmarket scenario for the generation of data to decide further on such FDCs falling under the category 'd' as per the report of the Committee.


    Subsequently, the directorate received representations from various stakeholders requesting for waiver of Phase IV clinical trial. The matter was examined by the directorate, in consultation with Prof. Kokate Committee and after due deliberation, the Committee recommended for categorization of these FDCs into following sub-groups namely-




    • FDCs which require Phase IV trial (Post Marketing Trial/Bioequivalence Study) as per Drugs & Cosmetics Rules, 1945.



    • FDCs for which Active Post Marketing Surveillance shall be conducted under intimation to DCG(I) and report shall be submitted for further evaluation.


    Further, the directorate also received representations from the subsequent applicants for obtaining NOC for manufacturing and marketing FDCs falling under category 'd' to have a level playing field. The list of FDCs falling under category 'd' is enclosed as Annexure A'.


    With the approval of the Ministry, it has been now decided to follow the pathway for clearance of such subsequent applications as under:-


    1. Documents required in case of manufacturers already holding licenses from State Licensing Authority (SLA) before 01.10.2012 for the proposed FDCs shall at least contain:-




    • Form CT 21(duly filled, signed and stamped)

    • Fees as specified in the sixth schedule of New Drugs and Clinical Trials Rule 2019 through Bharatkosh.

    • Name and composition of the FDC

    • Product Permission issued by SLA

    • Copy of Manufacturing license in Form 25/28

    • SI. no. and name of FDC as per the "Annexure A" and

    • Phase IV trial protocol/commitment for conducting Active Post Marketing Surveillance study/Bio-equivalence study protocol, as the case may be.


    2. Documents required in case of new manufacturers for the proposed FDCs shall at least contain:-




    • Form CT 21(duly filled, signed and stamped)

    • Fees as specified in the sixth schedule of New Drugs and Clinical Trials Rules 2019 through Bharat Kosh.

    • Name and composition of the FDC

    • Product Permission issued by SLA in Form 29

    • Copy of Manufacturing license in Form 25/28

    • SI. no. and name of FDC as per the "Annexure A"

    • Stability studies data (06 months accelerated)

    • Test Specifications of the FDC along with Method of Analysis

    • Phase IV trial protocol/commitment for conducting Active Post Marketing Surveillance study/Bio-equivalence the study protocol, as the case may be.


    3. All the manufacturers who are already holding licenses from State Licensing Authorities for such FDCs before01.10.2012 and did not apply to DCG (I) are required to submit their applications to the directorate at the earliest but not later than 6 months, failing which their applications will not be considered and their licenses will be considered as without legal validity.


    In view of the above, all concerned stakeholders are required to follow the above procedure for clearance of such cases.


    List of FDCs falling under category "d" as per Prof. Kokate Committee Report reads;


    https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NDQ2MA==


    Also Read: FDC Rationality: Now 6 months accelerated stability study data to be submitted, directs DCGI

    CDSCO DCGI Drug controllers FDC FDCs Fixed Dose Combination fixed dose combinations fixed dose drugs Government of India govt of india indian govt Marketing Surveillance Ministry of Health and Family Welfare New Drugs and Clinical Trials Rules 2019 Paracetamol paracetamol combination paracetamol combinations Phase IV Phase IV trial state drug controllers union territory UT drug controller 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X